Application of lung-heat-clearing stonecrop medicine composition to preparation of anti-influenza A virus medicine

A technology of influenza A virus and its composition, which is applied in the field of medicine and can solve the problems that have not yet been reported on the application of Sedum Qingfei medicinal composition of influenza A virus.

Active Publication Date: 2014-03-12
JINHE TIBETAN MEDICINE
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] After literature and patent searches, there is no report on the application of Sedum Qingfei medicinal composition in anti-influenza A virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lung-heat-clearing stonecrop medicine composition to preparation of anti-influenza A virus medicine
  • Application of lung-heat-clearing stonecrop medicine composition to preparation of anti-influenza A virus medicine
  • Application of lung-heat-clearing stonecrop medicine composition to preparation of anti-influenza A virus medicine

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0024] Experimental example 1, the preparation of the active ingredient of Jingtian Qingfei medicinal composition

[0025] 1. Raw materials: Rhodiola rosea 300g, travertine 300g, bellflower 200g, licorice 200g;

[0026] 2. Steps:

[0027] (1) Travertine is taken according to the ratio of the raw material medicine, and crushed into fine powder;

[0028] (2) Take rhodiola rosea, bellflower and licorice according to the ratio of the raw materials, add ethanol with a volume percentage of 60% to 80% and boil for two extractions: according to the volume / weight ratio, the amount of ethanol added for the first time is 1 / 2 of the total weight of the medicinal materials. 8 times, extract for 2 hours; according to the volume / weight ratio, the amount of ethanol added for the second time is 8 times of the total weight of the medicinal materials, extract for 1 hour, combine the extracts, filter, recover ethanol under reduced pressure, concentrate, and dry to obtain the extract A;

[0029...

experiment example 2

[0036] Experimental example 2, in vitro anti-influenza virus test

[0037] 1. Test material

[0038] Strain: Influenza A virus (A / FM1 / 1 / 47), provided by the Microbiology Laboratory of Shandong University of Traditional Chinese Medicine, routinely inoculated into the allantoic cavity of 9-11d embryonic chicken embryos, collected allantoic fluid, and determined red blood cell agglutination Activity, hemagglutination titer ≥ 320, negative bacterial culture, store at -60°C;

[0039] Cell model: dog kidney cell MDCK cells (provided by Shandong University of Traditional Chinese Medicine), cell growth medium is DMEM solution containing 10% calf serum, penicillin, streptomycin, gentamicin and sodium bicarbonate, for in vitro antiviral experiments The maintenance solution does not contain calf serum, but contains trypsin at a concentration of 2 μg / ml.

[0040]Positive control drug: Ribavirin, Jiangxi Gannan Pharmaceutical Factory, batch number 20110916;

[0041] Original preparation...

experiment example 3

[0054] Experimental example 3, in vivo anti-influenza virus test

[0055] 1. Test material

[0056] Strain: Influenza A virus (A / FM1 / 1 / 47), provided by the Microbiology Laboratory of Shandong University of Traditional Chinese Medicine, routinely inoculated into the allantoic cavity of 9-11d embryonic chicken embryos, collected allantoic fluid, and determined red blood cell agglutination Activity, hemagglutination titer ≥ 320, negative bacterial culture, store at -60°C;

[0057] Cell model: dog kidney cell MDCK cells (provided by Shandong University of Traditional Chinese Medicine), cell growth medium is DMEM solution containing 10% calf serum, penicillin, streptomycin, gentamicin and sodium bicarbonate, for in vitro antiviral experiments The maintenance solution does not contain calf serum, but contains trypsin at a concentration of 2 μg / ml.

[0058] Positive control drug: Ribavirin, Jiangxi Gannan Pharmaceutical Factory, batch number 20110916;

[0059] Original preparation...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a lung-heat-clearing stonecrop medicine composition to preparation of anti-influenza A virus medicine. The lung-heat-clearing stonecrop medicine composition is prepared from the following raw materials in weight part: 300 parts of rhodiola rosea, 300 parts of travertine, 200 parts of platycodon grandiflorum and 200 parts of liquorice. The lung-heat-clearing stonecrop medicine composition is a lung-heat-clearing stonecrop capsule or a pharmaceutical preparation which is prepared after the medicinal materials in a prescription are prepared into active ingredients, and the pharmaceutical preparation can be a sugarcoated tablet, a thin membrane coated tablet or a capsule preparation. The pharmacological experiments show that the lung-heat-clearing stonecrop medicine composition has a certain inhibition effect on influenza A in vitro and in vivo, can remarkably inhibit the influenza A virus-induced pulmonary index increase in miceinhibit the influenza A virus-induced pulmonary index increase in mice, remarkably inhibit the influenza A viruses to reduce immune organs in mice, remarkably prevent the influenza viruses from killing the mice, and has a significant regulating effect on hypoimmunity caused by virus infection. Moreover, the protective effect of the lung-heat-clearing stonecrop medicine composition prepared by a novel process is commensurate with that of virazole.

Description

technical field [0001] The invention relates to the application of a sedum sedum clearing lung medicine composition in the preparation of anti-influenza A virus medicine, which belongs to the field of medicine. Background technique [0002] Influenza virus, referred to as influenza virus for short, can cause acute upper respiratory tract infection and spread rapidly through the air. Influenza viruses are divided into three types: A (A), B (B), and C (C), which are the pathogens of influenza (flu). Among them, the antigenicity of influenza A virus is easy to mutate, causing worldwide pandemics many times. For example, in the pandemic from 1918 to 1919, at least 20 million to 40 million people died of influenza worldwide. In recent years, the emergence of avian influenza virus A (H5N1) and 2009 pandemic influenza virus A (H1N1) has once again aroused people's attention to influenza viruses. [0003] Jingtian Qingfei Capsule is recorded in the national standard part of local...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/484A61P31/16A61K33/10
Inventor 张义智邵成雷付素心单玉刚姬涛
Owner JINHE TIBETAN MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap